Mark Fishman

... which was a little over 20 years ago.

And I went to Novartis Institutes, which was founded by Mark Fishman when he was recruited by the then CEO of Novartis, Dan Vasella, to reimagine how research and early clinical development are done in industry.

And they basically brought the whole concept of translational medicine to industry.

Now, that term, I think, was coined at Oxford, somewhere in the UK-

And the things that we can talk about are how do you get a new regulatory pathway established, been part of that once, soup to nuts, and, and then how do you sort of create new indications? That's also a, a challenge.

Maybe it would be informative to think about how my team and I started something called the New Indication Discovery Unit at Novartis.

So Mark Fishman, who was the president of Novartis Research at the time, had a few of us come into his office and said, "We need to make the most needed medicines and find out what we're not doing that we should be doing and get it started." And, and we had a budget for that.

So super.

In the end, decided I really liked more of the business side, had a great chance at Ray Biopharma to kind of start cutting my teeth in that space.

The opportunity to come to Novartis, Nibber at the time when Mark Fishman was heading research, and really thinking about how a large pharmaceutical company could think about innovation and really headquartering.

It was one of the first big pharmas to really put a big stamp on the Kendall Square ecosystem.

It was just an amazing opportunity.